European Heart Journal vs Journal of Clinical Oncology: Which Journal Should You Choose?

EHJ asks whether the paper matters to cardiologists. JCO asks whether the paper matters to oncologists.

That's the whole decision in one sentence.

If the manuscript depends on ESC relevance, cardiovascular surveillance, imaging, heart-failure logic, or cardiac outcomes interpretation, EHJ usually becomes the better home. If the manuscript depends on treatment strategy, oncology outcomes, survivorship implications, or broad cancer-care interpretation, JCO usually becomes the better home.

EHJ wins when the cardio-oncology manuscript is fundamentally a cardiovascular paper.

That usually means:

• cardiotoxicity surveillance and management
• cardiovascular risk after cancer therapy
• imaging or biomarker work that cardiologists must act on
• cardio-oncology registry or observational studies with clear cardiovascular practice implications

The EHJ source set repeatedly emphasizes broad cardiology consequence, ESC-facing context, and field-wide importance.

JCO wins when the manuscript is fundamentally an oncology paper.

That includes:

• clinical oncology studies where cardiac endpoints matter but are still part of a broader oncology question
• survivorship work where the central decisions still belong to oncologists
• treatment interpretation or outcomes papers whose main audience is cancer clinicians
• broad oncology analyses where cardiovascular risk is important, but not the primary readership driver

The JCO sources are clear that the journal wants broad oncology consequence and a complete evidence package for oncology readers.

EHJ's submission logic is cardiology-first

submission's editorial guidance pushes authors to connect findings to ESC guidelines, European cardiovascular practice, registries, and broad cardiology consequence. That's a signal that the paper belongs there only if the cardiovascular angle is the real headline.

JCO is built for broad clinical oncology

JCO fit and submission's editorial guidance repeatedly emphasize broad oncology readership, treatment interpretation, and high-consequence clinical or translational work. That makes it a much better home for oncology-led cardio-oncology studies than many cardiology journals.

EHJ is more comfortable with cardiology-native framing

Cardiology language, cardiovascular risk logic, and imaging or outcome nuance aren't weaknesses there. They're expected.

JCO is more comfortable with oncology-native framing

Oncology treatment logic, patient management, and cancer-outcome reasoning are expected there, even when cardiovascular toxicity is a major component.

• the paper is fundamentally cardiovascular
• cardiologists are the main audience
• cardiovascular outcomes, surveillance, or ESC-facing relevance are central
• the manuscript becomes stronger when written for cardiology readers

That's the EHJ lane.

• the paper is fundamentally oncology-led
• oncologists are the main audience
• treatment strategy, survivorship, or broad oncology consequence is central
• the manuscript becomes stronger when written for oncology readers

That's the JCO lane.

This isn't a simple prestige cascade.

A paper rejected by EHJ does not automatically become a JCO paper, and vice versa.

The cascade only works when the first journal saw the manuscript as belonging more naturally to the other specialty.

That can happen when:

• the paper sits at the cardio-oncology boundary
• the methods are strong
• the question is important to both fields
• the first journal judged that the primary readership was actually the other specialty

It doesn't work when the study is simply too narrow or too weak for either field-leading journal.

EHJ punishes papers that are too oncology-defined

If the cardiovascular consequence feels secondary to the cancer story, EHJ gets harder quickly.

JCO punishes papers that are too cardiology-defined

If the main practical readers are cardiologists and the oncology story is mostly context, JCO gets harder quickly.

EHJ punishes narrow cardiovascular consequence

The journal still wants broad cardiology importance, not only a decent cardio-oncology analysis.

JCO punishes oncology papers that are too limited in field consequence

Interesting but narrow results often look better in a more focused oncology title.

Cardiotoxicity monitoring and cardiovascular outcomes

These are usually cleaner EHJ papers when the goal is to change cardiovascular practice.

Cancer-treatment or survivorship studies with cardiac endpoints

These are often cleaner JCO papers when the main decisions still belong to oncologists.

Registry and cohort papers

The key question is which field's readers need the evidence first. That usually tells you the right target.

Cardio-oncology supportive care papers

These can go either way, but only if the manuscript is honest about whether the intervention or implication is oncology-led or cardiology-led.

A strong EHJ first page makes the cardiovascular consequence obvious immediately. The reader should understand why cardiologists need this paper now.

A strong JCO first page makes the oncology consequence obvious immediately. The reader should understand why oncologists need this paper now.

If both first pages sound equally necessary, the manuscript may still be undecided about its true audience.

Ask which sentence fits the manuscript better:

• "this changes what cardiologists should do or think" points toward European Heart Journal
• "this changes what oncologists should do or think" points toward Journal of Clinical Oncology

That sentence is often the most honest submission test.

At the cardio-oncology boundary, the wrong readership can make a very good paper feel strangely secondary. A study that's perfect for cardiologists can look too supportive for oncologists. A study that's perfect for oncologists can look only indirectly actionable for cardiologists.

That's why audience clarity matters more here than prestige reflexes.

Send to European Heart Journal first if:

1. the paper is fundamentally cardiovascular
2. cardiologists are the readers who most need it
3. ESC-facing relevance or cardiovascular management is central
4. the paper gets stronger when written for cardiology

Send to Journal of Clinical Oncology first if:

1. the paper is fundamentally oncology-led
2. oncologists are the readers who most need it
3. treatment strategy or oncology management is central
4. the paper gets stronger when written for oncology

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.